Blood MSI dynamics as a predictive biomarker of immune checkpoint inhibitor therapy efficacy in colorectal cancer (CRC): preliminary results from an observational trial

被引：0
|
作者：
Byakhova, M. [1 ]
Veselovsky, E. [1 ]
Yudina, V. [1 ]
Kuznetsova, O. [1 ]
Kravchuk, D. [1 ]
Lebedeva, A. [1 ]
Belova, E. [1 ]
Taraskina, A. [1 ]
Grigoreva, T. [1 ]
Kavun, A. [1 ]
Nikulin, V. [1 ]
Mileyko, V. [1 ]
Tryakin, A. [1 ]
Fedyanin, M. [1 ]
Ivanov, M. [1 ]
机构：
[1] City Clin Oncol Hosp 1, Novosibirsk, Russia
来源：
VIRCHOWS ARCHIV | 2024年 / 485卷
基金：
俄罗斯科学基金会;
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
E-PS-19-01
引用
收藏
页码：S422 / S422
页数：1
相关论文
共 50 条
  • [31] Cetuximab plus capecitabine plus irinotecan (CCI) versus cetuximab plus capecitabine plus oxaliplatin (CCO) as first line therapy for patients with metastatic colorectal cancer (CRC): Preliminary results of a randomized phase II trial of the AIO CRC Study Group.
    Heinemann, V.
    Von Weikersthal, L. Fischer
    Moosmann, N.
    Vehling-Kaiser, U.
    Stauch, M.
    Oruzio, D.
    Schulze, M.
    Walther, J.
    Weiss, J.
    Dietzfelbinger, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 158S - 158S
  • [32] Baseline Circulating Blood Cell Counts and Ratios and Changes Therein for Predicting Immune-Related Adverse Events during Immune Checkpoint Inhibitor Therapy: A Multicenter, Prospective, Observational, Pan-Cancer Cohort Study with a Gender Perspective
    Teijeira, Lucia
    Martinez, Mireia
    Moreno, Amaia
    de Elejoste, Ibone
    Ibanez-Beroiz, Berta
    Arrazubi, Virginia
    de Corcuera, Isabela Diaz
    Elejalde, Inaki
    Campillo-Calatayud, Ana
    Les, Inigo
    CANCERS, 2024, 16 (01)
  • [33] Dual-targeted therapy with pyrotinib and trastuzumab for HER2-positive advanced colorectal cancer: Preliminary results from a multicenter phase 2 trial.
    Yuan, Ying
    Fu, Xianhua
    Ying, Jieer
    Yang, Liu
    Fang, Weijia
    Han, Weidong
    Zhang, Suzhan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [34] Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial
    Rini, Brian, I
    Moslehi, Javid J.
    Bonaca, Marc
    Schmidinger, Manuela
    Albiges, Laurence
    Choueiri, Toni K.
    Motzer, Robert J.
    Atkins, Michael B.
    Haanen, John
    Mariani, Mariangela
    Wang, Jing
    Hariharan, Subramanian
    Larkin, James
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17) : 1929 - +
  • [35] Adding Cetuximab to a Standard Chemotherapy Regimen Containing Bevacizumab in First-Line Therapy for Colorectal Cancer Decreases Efficacy: Results From the CAIRO2 Trial
    Grothey, Axel
    CURRENT COLORECTAL CANCER REPORTS, 2009, 5 (02) : 65 - 66
  • [36] C-REACTIVE PROTEIN (CRP) AS A PROGNOSTIC BIOMARKER IN ADVANCED NON-SMALL CELL LUNG CANCER TREATED WITH IMMUNE CHECKPOINT INHIBITORS. RESULTS FROM A MULTI-CENTER INTERNATIONAL OBSERVATIONAL STUDY
    Naqash, Abdul Rafeh
    Cortellini, Alessio
    Mi, Emma
    Livanainen, Sanna
    Gramenitskaya, Daria
    Clark, James
    O'Brien, Kevin
    Koivunen, Jussi
    Macherla, Shravanti
    Jonnalagadda, Sweta
    Polsani, Shanker
    Jiwani, Rahim
    Sharma, Nitika
    Stroud, Chipman
    Muzaffar, Mahvish
    Walker, Paul
    Pinato, David
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A18 - A18
  • [37] BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response-Preliminary results from the SCLC cohort.
    Fischer, Rieke Nila
    George, Julie
    Scheel, Andreas H.
    Schloesser, Hans Anton
    Vehreschild, Maria
    Brossart, Peter
    Engel-Riedel, Walburga
    Griesinger, Frank
    Grohe, Christian
    Kambartel, Karl-Otto
    Kern, Jens
    Hermes, Barbara
    Nachtkamp, Kathrin
    Panse, Jens Peter
    Sebastian, Martin
    Lehmann, Markus
    Wiewrodt, Rainer Gerhard
    Buettner, Reinhard
    Thomas, Roman K.
    Wolf, Juergen
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [38] Monitoring early clearance of circulating tumor DNA as an effective tool to predict clinical benefits of immune checkpoint inhibitors in lung cancer patients: The preliminary results from clinical trial NCT04203095.
    Di Zheng
    Jian Ni
    Yi Zhong
    Qian Ziliang
    Wang, Baiyun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [39] Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer
    Kenji Morimoto
    Tadaaki Yamada
    Ryo Sawada
    Koichi Azuma
    Yasuhiro Goto
    Taishi Harada
    Shinsuke Shiotsu
    Nobuyo Tamiya
    Yusuke Chihara
    Takayuki Takeda
    Osamu Hiranuma
    Isao Hasegawa
    Satomi Tanaka
    Akihiro Yoshimura
    Masahiro Iwasaku
    Shinsaku Tokuda
    Young Hak Kim
    Koichi Takayama
    Cancer Immunology, Immunotherapy, 2023, 72 : 1699 - 1707
  • [40] Evaluation of a BRCAness signature as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 trial
    Glas, A.
    Peeters, J.
    Yau, C.
    Wolf, D. M.
    Sanil, A.
    Li, Y.
    Severson, T.
    Linn, S.
    Buxton, M.
    DeMichele, A.
    Hylton, N.
    Symmans, F.
    Yee, D.
    Paoloni, M.
    Esserman, L.
    Berry, D.
    Rugo, H.
    Olopade, O.
    van 't Veer, L. J.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 173 - 173
12345